Streetbeat News

Partnerships

SLGL

Sol-Gel Technologies Ltd (NASDAQ:SLGL) announced a virtual KOL event on December 6, 2023, to discuss Gorlin Syndrome and the Phase 3 trial for SGT-610, a potential treatment. SGT-610 has received Orphan Drug and Breakthrough Designations from the FDA. The event will feature discussions on the disease burden, SGT-610's therapeutic potential, and market insights. Julie Breneiser from the Gorlin Syndrome Alliance and Dr. Ervin Epstein Jr., a dermatologist and co-founder of PellePharm Inc., will speak at the event.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:21 pm

G

Genpact (NYSE:G), a global professional services firm, has released an industry-first playbook for scaling responsible generative AI projects, called FMOps – The Generative AI Imperative for Production. Developed with Nasscom, it provides guidelines for transitioning from pilot to production generative AI projects, focusing on Foundation Model Operations (FMOps) and including Large Language Model Operations (LLMOps) and Machine Learning Operations (MLOps). The playbook emphasizes the need for ethical and scalable solutions, improved collaboration, faster release cycles, and risk reduction in AI systems.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:21 pm

TWKS

Thoughtworks (NASDAQ:TWKS), a global technology consultancy, announced its expansion into Switzerland as part of its strategy to scale up in key European industry verticals. The company, which serves financial and health services clients, aims to grow its market presence in Europe and provide enhanced service to its Swiss clients, including SMG Swiss Marketplace Group and V-Zug.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:18 pm

ARE

LLY

Alexandria Real Estate Equities, Inc. (ARE) has announced an exclusive partnership with Eli Lilly and Company (LLY) to expand Lilly Gateway Labs to San Diego, aiming to accelerate the development of early-stage life science companies. The new site will be located in Alexandria's University Town Center submarket, providing emerging biotech companies with laboratories, collaboration opportunities with Lilly, and access to capital. This initiative builds on the strategic relationship between ARE and LLY since 2008 and leverages San Diego's thriving life science ecosystem. The Gateway Labs San Diego site is expected to open in the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:16 pm

FOR

Forestar Group Inc. announced the retirement of CEO Daniel C. Bartok and the appointment of Anthony W. Oxley as the new CEO, effective January 1, 2024. Oxley, currently serving as Senior VP at D.R. Horton, brings extensive experience in land acquisition and development. Bartok will remain in a consulting role to ensure a smooth transition. The leadership change aims to continue Forestar's growth as a leading residential lot developer.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:15 pm

ACN

SAP

Accenture Plc (NYSE:ACN) is set to acquire Ammagamma, an Italian AI firm, to enhance its European AI capabilities. The acquisition aligns with Accenture's $3 billion investment plan to aid client transformation through AI. Ammagamma brings a team of 90 AI professionals to Accenture's Advanced Center for AI in Europe. Additionally, Accenture announced a collaboration with SAP SE (NYSE:SAP) to reinvent supply chains, aiming to reduce risk and support sustainability. Accenture's cash position was $9.04 billion as of August 31, 2023. ACN shares closed slightly lower at $332.43.

Portfolio Pulse from Shivani Kumaresan

November 28, 2023 | 1:15 pm

GEHC

ICAD

iCAD, Inc. has announced that its applications from the iCAD Breast Health Suite are now integrated into GE HealthCare's MyBreastAI Suite. This integration is expected to enhance the capabilities of GE HealthCare's suite by incorporating iCAD's advanced breast health technologies.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:13 pm

LCFY

Locafy Limited (NASDAQ: LCFY), a SaaS company specializing in local search engine marketing, announced promising trial results for its Article Accelerator product. The trials, conducted with a major U.S.-based media publisher, showed significant increases in online visibility metrics for advertorials. The technology led to up to 71% increases in impression and visitor counts and a 193% increase in keyword rankings. Locafy's CEO, Gavin Burnett, expressed confidence in the technology's market potential and its ability to offer value to media organizations. The company has restructured its teams for scalable production and is conducting additional trials with a second media partner.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:13 pm

CRL

Charles River Laboratories International, Inc. (NYSE:CRL) and Genetic Cures for Kids Inc (GC4K) have announced a collaboration for plasmid DNA production to support early phase trials for SPG56 Hereditary Spastic Paraplegia. Charles River will utilize its eXpDNA™ platform and HQ Plasmid Manufacturing Center of Excellence to aid in the development of a gene therapy for SPG56, a rare neurodegenerative disease with no current treatment. The partnership aims to create a framework for treating other genetic diseases.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:12 pm

TMO

Thermo Fisher Scientific has formed a strategic partnership with Flagship Pioneering to develop and scale multiproduct platforms aimed at accelerating the creation of first-in-class therapies. This collaboration builds on their existing supply relationship and will leverage both companies' expertise in life science tools, diagnostics, and services to support the biotech ecosystem.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:10 pm